JP2016516721A - トキソイド、組成物および関連方法 - Google Patents

トキソイド、組成物および関連方法 Download PDF

Info

Publication number
JP2016516721A
JP2016516721A JP2016502966A JP2016502966A JP2016516721A JP 2016516721 A JP2016516721 A JP 2016516721A JP 2016502966 A JP2016502966 A JP 2016502966A JP 2016502966 A JP2016502966 A JP 2016502966A JP 2016516721 A JP2016516721 A JP 2016516721A
Authority
JP
Japan
Prior art keywords
toxoid
difficile
toxin
formaldehyde
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516721A5 (https=
Inventor
ハウザー，スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Sanofi Pasteur Inc
Original Assignee
Aventis Pasteur SA
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA, Sanofi Pasteur Inc filed Critical Aventis Pasteur SA
Publication of JP2016516721A publication Critical patent/JP2016516721A/ja
Publication of JP2016516721A5 publication Critical patent/JP2016516721A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2016502966A 2013-03-15 2014-03-14 トキソイド、組成物および関連方法 Pending JP2016516721A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
US61/790,423 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (2)

Publication Number Publication Date
JP2016516721A true JP2016516721A (ja) 2016-06-09
JP2016516721A5 JP2016516721A5 (https=) 2017-05-18

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502966A Pending JP2016516721A (ja) 2013-03-15 2014-03-14 トキソイド、組成物および関連方法

Country Status (13)

Country Link
US (2) US20160045586A1 (https=)
EP (1) EP2968507A2 (https=)
JP (1) JP2016516721A (https=)
KR (1) KR20150133770A (https=)
CN (1) CN105338997A (https=)
AR (1) AR095669A1 (https=)
AU (1) AU2014228956A1 (https=)
BR (1) BR112015023332A2 (https=)
CA (1) CA2907154A1 (https=)
HK (1) HK1213800A1 (https=)
SG (1) SG11201507608PA (https=)
TW (1) TWI624474B (https=)
WO (1) WO2014144567A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020522471A (ja) * 2017-06-09 2020-07-30 ヒプラ シエンティフィック エセ．エレ．ウ． クロストリジウム類毒素を含むワクチン

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6691477B2 (ja) * 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
JP2024546686A (ja) * 2021-12-06 2024-12-26 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 癌を治療するための組成物及び方法
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030494A1 (en) * 1995-03-31 1996-10-03 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin a and production of mono-specific antibodies
US20030215468A1 (en) * 1995-03-16 2003-11-20 Allergan, Inc., Allergan Botox Limited Soluble recombinant botulinum toxin proteins
JP2007514749A (ja) * 2003-12-16 2007-06-07 アカンビス インコーポレーティッド クロストリジウムディフィシル疾患に対する受動免疫感作
WO2012007728A2 (en) * 2010-07-16 2012-01-19 The Secretary Of State For Defence Toxoiding method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305293A3 (en) * 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
MX2010001054A (es) 2007-07-26 2010-04-21 Sanofi Pasteur Ltd Composiciones adyuvantes antigenicas y metodos.
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215468A1 (en) * 1995-03-16 2003-11-20 Allergan, Inc., Allergan Botox Limited Soluble recombinant botulinum toxin proteins
WO1996030494A1 (en) * 1995-03-31 1996-10-03 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin a and production of mono-specific antibodies
JP2007514749A (ja) * 2003-12-16 2007-06-07 アカンビス インコーポレーティッド クロストリジウムディフィシル疾患に対する受動免疫感作
WO2012007728A2 (en) * 2010-07-16 2012-01-19 The Secretary Of State For Defence Toxoiding method

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020522471A (ja) * 2017-06-09 2020-07-30 ヒプラ シエンティフィック エセ．エレ．ウ． クロストリジウム類毒素を含むワクチン
JP7349366B2 (ja) 2017-06-09 2023-09-22 ヒプラ シエンティフィック エセ．エレ．ウ． クロストリジウム類毒素を含むワクチン

Also Published As

Publication number Publication date
US20180028637A1 (en) 2018-02-01
SG11201507608PA (en) 2015-10-29
KR20150133770A (ko) 2015-11-30
US20160045586A1 (en) 2016-02-18
CA2907154A1 (en) 2014-09-18
WO2014144567A2 (en) 2014-09-18
AR095669A1 (es) 2015-11-04
WO2014144567A3 (en) 2014-12-04
TW201514197A (zh) 2015-04-16
AU2014228956A1 (en) 2015-10-08
CN105338997A (zh) 2016-02-17
HK1213800A1 (zh) 2016-07-15
BR112015023332A2 (pt) 2017-08-22
TWI624474B (zh) 2018-05-21
EP2968507A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
JP2016516721A (ja) トキソイド、組成物および関連方法
US9561269B2 (en) Neisseria meningitidis compositions and methods thereof
US11472850B2 (en) Neisseria meningitidis composition and methods thereof
CN102238960B (zh) 制造疫苗的方法
JP2016519671A (ja) トキソイド、組成物および関連方法
JP2016519671A5 (https=)
US20180110849A1 (en) Methods for immunizing against clostridium difficile
EP0563288B1 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
CN111467488A (zh) 一种水溶性复合免疫佐剂及其应用
Kumar et al. Immunological studies on a modified multiple emulsion (w/o/w) bivalent Haemmorhagic septicemia vaccine incorporated with Pasteurella multocida P52 in the external aqueous phase
JPH02101023A (ja) オーエスキー病のサブユニットワクチン、及び製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181031